Prevalence of underlying diseases in died cases of COVID-19: A systematic review and meta-analysis

Abstract

Introduction Underlying disease have a critical role in vulnerability of populations for a greater morbidity and mortality when they suffer from COVID-19. The aim of current study is evaluating the prevalence of underlying disease in died people with COVID-19. Methods The current study have been conducted according to PRISMA guideline. International database including PubMed, Scopus, Web of Science, Cochrane and google scholar were searched for relevant studies up to 1 June. All relevant articles that reported underlying disease in died cases of COVID-19 were included in the analysis. Results After screening and excluding duplicated and irrelevant studies, 32 articles included in the analysis. The most prevalent comorbidities were hypertension, diabetes, cardiovascular disease, liver disease, lung disease, malignancy, cerebrovascular disease, COPD and asthma. Among all reported underlying disease, highest and lowest prevalence was related to hypertension and asthma which were estimated 46% (37% - 55%) and 3% (2%- 6%), respectively. Conclusion In summary, underlying disease have a critical role in poor outcomes, severity of disease and high mortality rate of COVID-19 cases. Patients with hypertension, cardiovascular disease and diabetes should be carefully monitored and be aware of health protocols.

Underlying Kidney Diseases and Complications for COVID-19: A Review

“…A systematic review and metaanalysis indicate a 1% (95% CI, 1-2%) pooled prevalence of chronic kidney diseases with about 83.9% suffering a severe COVID-19 that resulted in a 53% mortality rate (21). Chronic kidney disease (CKD) is one of the common underlying diseases among COVID-19 hospitalized patients (22).…”

COVID-19 in patients with Down syndrome

“…COVID-19 is primarily a respiratory illness, but patients may experience a severe illness characterized by multi-organ failure and death [ 1 ]. The main risk factors for a more severe COVID-19 have been recognized as older age, diabetes mellitus, chronic respiratory problems, hypertension, and cardiovascular disorders, among others [ 1 , 2 ].…”

Providing safe perioperative care in cardiac surgery during the COVID-19 pandemic

“…[ 1 , 2 , 3 , 4 , 5 , 6 ] Cardiovascular diseases, especially arterial hypertension, and comorbidities including diabetes, obesity, age > 65 years, chronic pulmonary disease, and evidence of immunosuppression are most commonly associated with worse prognosis in hospitalized COVID-19 patients. [ 3 , 4 , 7 , 8 ] Myocardial injury is frequently reported in COVID-19 cases and is associated with increased risk of arrhythmia or death. [ 9 ] Although myocarditis, stress cardiomyopathy and type I myocardial infarction were reported as direct consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the most common etiology of myocardial injury or type II myocardial infarction remain non-cardiac conditions like respiratory failure with hypoxia and sepsis.…”

“…[ 53 , 54 ] Although the latter may be treated with veno-venous extracorporeal membrane oxygenation support (ECMO), the overall mortality at 90 days after ECMO support in COVID-19 remains high at 39 %. [ 8 , 55 ] Specifically in patients who present with acute heart failure or cardiogenic shock, and in whom a concomitant COVID-19 infection is suspected, the use of ECMO should be weighed against the increased risk for coagulopathy disorders, as well as the need for specific treatment of acute respiratory failure, such as prone positioning. Specifically in COVID-19 patients who develop acute heart failure, significantly elevated mortality of 52% has been observed, compared to 12% in COVID-19 patients without acute heart failure.…”